Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Hyaluronidase|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Acalabrutinib||Calquence||ACP-196||BTK inhibitor 27||Calquence (acalabrutinib) selectively inhibits BTK, resulting in decreased B-cell receptor signaling, and potentially leading to decreased tumor cell proliferation (PMID: 27903679, PMID: 26957112). Calquence (acalabrutinib) is FDA approved for use in patients with mantle cell lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma (FDA.gov).|
|Bortezomib||Velcade||Velcade (bortezomib) is a reversible proteasome inhibitor that inhibits survival of malignant cells and regulates bone remodeling (PMID: 26579531). Velcade (bortezomib) is FDA approved for the treatment of mantle cell lymphoma and multiple myeloma (FDA.gov).|
|Cyclophosphamide||Cytoxan||CPM||Chemotherapy - Alkylating 16||Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary).|
|Doxorubicin||Adriamycin||Adria|ADR|Doxorubicin hydrochloride|Hydroxydaunorubicin||Chemotherapy - Anthracycline 11 TOPO2 inhibitor 5||Adriamycin (doxorubicin) is an anthracycline chemotherapeutic, in a non-liposomal formulation, which intercalates into DNA and inhibits topoisomerase II (PMID: 24367159). Doxorubicin is FDA approved for multiple cancer types (FDA.gov).|
|Prednisone||Adasone||Dehydrocortisone||Adasone (prednisone) is a corticosteroid which functions as an immunosuppressant and anti-inflammatory agent and which may stimulate apoptosis in tumor cells (NCI Drug Dictionary).|
|Rituximab Hyaluronidase||Rituxan Hycela|Rituximab and Hyaluronidase Human|Rituximab/Hyaluronidase||CD20 Antibody 12||Rituximab Hyaluronidase consists of a preparation of the CD20 antibody Rituxan (rituximab) combined with hyaluronidase, which upon delivery leads to break down of tissue hyaluronan by the hyaluronidase component, resulting in increased rituximab absorption and potentially resulting in enhanced complement-dependent and antibody-dependent cytotoxicity against CD20-positive tumor cells (NCI Drug Dictionary).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT04626791||Phase II||Acalabrutinib + Cytarabine + Rituximab Hyaluronidase Acalabrutinib + Cytarabine + Rituximab Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Acalabrutinib + Bortezomib + Cyclophosphamide + Doxorubicin + Prednisone + Rituximab Hyaluronidase||Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma||Not yet recruiting||USA||0|